Search

124 Result(s)
Sort by

COVID-19 Protecting Our Employees

COVID-19 Protecting Our Employees

We have taken precautions to protect our employees health and mitigate the risk of COVID-19 affecting our organisation. Click here to find out more.
1988-2015

1988-2015

Following the death of Hubertus Liebrecht (1991), the owning family made some fundamental decisions regarding the company’s alignment. Learn more here.
1948-1988

1948-1988

Following the death of Albert Boehringer (1861-1939), his two sons and his son-in-law Julius Liebrecht took over this family company. Learn more.
Harold Heart and Friends

Harold Heart and Friends

The cardiovascular, renal and metabolic systems are interconnected and dysfunction in one system may lead to dysfunction in the other. Learn more here.
Innovation Through Cooperation

Innovation Through Cooperation

Exchange of information between pharmaceutical manufacturers and healthcare professionals is essential for patients. Click here to learn more.
COVID-19: Research Update

COVID-19: Research Update

Boehringer Ingelheim stops treatment with experimental medication in study investigating benefits for severely ill patients with COVID-19. Learn more.
EMPRISE

EMPRISE

Learn about the EMPRISE real-world evidence study and use of empagliflozin in routine clinical care. Click here to find out more information.
Pet industry trends Millennials
Millennials are now shaping pet markets and facing new issues in pet healthcare. Click here to read and learn more about this new generation of pet owners.
Guardians for health

Guardians for health

A global initiative to reduce mortality, cardiovascular and kidney complications in type 2 diabetes through adherence to clinical guidelines. Learn more.
One step further in fighting rabies in Vietnam

One step further in fighting rabies in Vietnam

A expedition team set off to the Duc Hue District. The purpose? To vaccinate the entire dog and cat population of several villages. Find out more.ral villages.
Lyon

Lyon

Boehringer Ingelheim has a research and production network across the globe. Click here to read and find out information about our Lyon site.
Innovation Needs Transparency

Innovation Needs Transparency

At Boehringer Ingelheim, we prioritise the establishment and maintenance of public trust. Transparency is therefore a key pillar of our corporate culture.
COVID-19 Mexico - The value of teamwork

COVID-19 Mexico - The value of teamwork

During the pandemic, Fabiola Villegas, contributed with creativity and ingenuity from her region in Uruapan, Michoacán, Mexico. Click here to learn more.
COVID-19 IMI2–Call 21

COVID-19 IMI2–Call 21

CARE launched to accelerate therapy development against COVID-19 and future coronavirus threats.